News, blogs and podcasts

Latest articles

1. New cystic fibrosis drug fast-tracked for NHS use

   Some people with cystic fibrosis are set to benefit from a new once-daily triple therapy treatment, following NICE's recommendation of Alyftrek in final draft guidance published today.

2. Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional costs to the NHS

   The benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.

3. ‘Artificial pancreas’ transforming the lives of thousands of children and young people with type 1 diabetes

   The innovative hybrid closed loop (HCL) systems offer improved blood sugar control and can transform daily life for families managing this complex condition. 

View all news articles

Latest blogs

• NICE responds to publication of the government’s Life Sciences Sector Plan

  We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing healthtech, while supporting a thriving life sciences industry in the UK.

• NHS 10 Year Health Plan empowers NICE to get patients better care, faster

  Dr Sam Roberts, NICE's chief executive, welcomes the government's 10 Year Health Plan, which marks a pivotal moment for healthcare and strengthens NICE’s role.

View all blogs